Gapping up
News:
- ALIM +75.2% (Alimera Sciences to be acquired by ANI Pharmaceuticals (ANIP) for $5.50/share in cash)
- ALNY +35.9% (Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations)
- RGLS +16.6% (Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease )
- RXO +13.8% (RXO, Inc. to acquire Coyote Logistics from UPS)
- ALT +12.3% (Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association's 84th Scientific Sessions; Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association's 84th Annual Scientific Sessions)
- CANF +11.7% (Breakthrough findings demonstrate Namodenoson anti-cancer and protective effect mechanism in the liver)
- ARGX +9.8% (FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy)
- RGNX +8.5% (initiated enrollment in a new cohort of patients ages 1-3 in its Phase I/II AFFINITY DUCHENNE trial to evaluate the safety and efficacy of RGX-202 in boys with Duchenne muscular dystrophy )
- CSTL +7% (announced that the latest American Gastroenterological Association clinical practice guideline recognized that not all patients with non-dysplastic BE are at low risk of developing esophageal cancer)
- DJT +6.8% (Announces $69.4 Million in Initial Proceeds from Warrant Exercise)
- ACET +6.6% (FDA has cleared the Company's Investigational New Drug application to evaluate ADI-270)
- PUK +6.4% (commencement of first tranche of share buyback program)
- DOMO +6.4% (Director disclosed the purchase of 400,000 shares at $6.58 - $7.00 worth approx. $2.7 mln)
- FREY +6% (provides operations update)
- CDLR +5.6% (signs firm contract for the installation of 72 15MW wind turbines at Inch Cape Offshore Wind Farm using one of Cadeler's state-of-the-art newbuild M-class wind turbine installation vessels)
- TRDA +5% (reports positive preliminary data in healthy volunteers from phase 1 ENTR-601-44-101 trial for duchenne muscular dystrophy; entered into a securities purchase agreement with a group of investors for the purchase of 3,367,003 shares of common stock and pre-funded warrants to purchase up to 3,367,003 shares of common stock in a registered direct offering for aggregate gross proceeds of ~$100 mln)
- AVTX +5% (provides investor updates in presentation; expected cash runway thru 2027)
- RANI +4.6% (has entered into a definitive agreement with ProGen Co. for the co-development and commercialization of RT-114, an oral RaniPill capsule containing ProGen's PG-102, a GLP-1/GLP-2 dual agonist, for the treatment of obesity)
- GUTS +4.4% (Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva Single-Administration GLP-1 Pancreatic Gene Therapy in President's Select Oral Presentation at the American Diabetes Association's 84th Scientific Sessions; announces advancement in weight maintenance pipeline and business updates)
- TERN +3.2% (Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA's 84th Annual Scientific Sessions and Upcoming Conference Participation)
- ARWR +3.1% (presents preclinical data on new RNAi-based obesity program ARO-INHBE)
- BHR +2.9% (Blackwells releases letter to fellow shareholders highlighting ongoing corporate piracy being carried out by Braemar Chairman Monty Bennett and His Cronies) MNKD +2.5% (Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association's 84th Scientific Sessions)
- MUFG +2.1% (reports completion on repurchase of common stock)
- BNTX +2.1% (BioNTech and DualityBio receive FDA Fast Track Designation for antibody-drug conjugate candidate BNT324/DB-1311 in prostate cancer)
- TAK +1.2% (Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer; Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia)
- VALN +1% (announces Health Canada approval of the world's first chikungunya vaccine, IXCHIQ)